Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in
current concepts of targeted cancer therapy for glioblastoma multiforme (GBM), the most …

Antibodies have been shown to be a potent therapeutic tool. However, their use for targeting
brain diseases, including neurodegenerative diseases and brain cancers, has been limited …

Personalized cancer treatments using combinations of drugs with a synergistic effect is
attractive but proves to be highly challenging. Here we present an approach to uncover the …

Glioblastoma, a grade 4 glioma as per the World Health Organization, poses a challenge in
adult primary brain tumor management despite advanced surgical techniques and …

Simple Summary Glioblastoma multiforme (GBM) is the most common type of malignant
brain tumor. GBM patients face a dire future, as they rarely survive longer than 15 months …

Glioblastoma (GBM) is a very aggressive CNS tumor with poor prognosis. Current treatment
lacks efficacy indicating that new therapeutic approaches are needed. One of these new …

To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we
developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize …

Introduction Gliomas are infiltrating brain tumors associated with high morbidity and
mortality. Current standard of care includes radiation, chemotherapy, and surgical resection …

Phosphatases and cancer have been related for many years now, as these enzymes
regulate key cellular functions, including cell survival, migration, differentiation and …

Background/Aims: Epidermal growth factor receptor variant III (EGFRvIII), the most frequent
EGFR variant, is constitutively activated without binding to EGF and is correlated with a poor …